NCT06232551 Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
| NCT ID | NCT06232551 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Scott C. Woller, MD |
| Condition | Venous Thromboembolic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 152,000 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 152,000 participants in total. It began in 2024-06-01 with a primary completion date of 2025-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.
Eligibility Criteria
Inclusion Criteria: * Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions: * Physician, nurse practitioner, or physician assistant hospitalist * Physician internal medicine * Physician family medicine * Patient age ≥ 18 years. * The encounter must be inpatient. * A signed hospital discharge order must be present. * eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met Exclusion Criteria: * Pregnant during encounter * Discharge order completed by ineligible clinician type * Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications): * Apixaban * Dabigatran * Dalteparin * Enoxaparin * Edoxaban * Betrixaban * Fondaparinux * Rivaroxaban * Warfarin * Creatinine clearance \<30 milliliters/minute based on last-available eligible serum creatinine value preceding discharge * Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \* measured weight kilograms) / (72.0 \* serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute * If measured body weight not available, then based on ideal body weight ((140 - age years) \* ideal body weight kilograms) / (72.0 \* serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute
Contact & Investigator
Scott C. Woller, MD
PRINCIPAL INVESTIGATOR
Intermountain Health
Frequently Asked Questions
Who can join the NCT06232551 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Venous Thromboembolic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06232551 currently recruiting?
Yes, NCT06232551 is actively recruiting participants. Contact the research team at valerie.aston@imail.org for enrollment information.
Where is the NCT06232551 trial being conducted?
This trial is being conducted at Murray, United States.
Who is sponsoring the NCT06232551 clinical trial?
NCT06232551 is sponsored by Scott C. Woller, MD. The principal investigator is Scott C. Woller, MD at Intermountain Health. The trial plans to enroll 152,000 participants.